Invention Grant
- Patent Title: Substituted inhibitors of menin-MLL and methods of use
-
Application No.: US16944040Application Date: 2020-07-30
-
Publication No.: US11673898B2Publication Date: 2023-06-13
- Inventor: Tao Wu , Liansheng Li , Yi Wang , Pingda Ren , Jolanta Grembecka , Tomasz Cierpicki , Szymon Klossowski , Jonathan Pollock , Dmitry Borkin
- Applicant: Kura Oncology, Inc. , The Regents of The University of Michigan
- Applicant Address: US CA San Diego
- Assignee: KURA ONCOLOGY, INC.,THE REGENTS OF THE UNIVERSITY OF MICHIGAN
- Current Assignee: KURA ONCOLOGY, INC.,THE REGENTS OF THE UNIVERSITY OF MICHIGAN
- Current Assignee Address: US CA San Diego; US MI Ann Arbor
- Agency: Wilson Sonsini Goodrich & Rosati
- The original application number of the division: US16082649
- Main IPC: C07D495/04
- IPC: C07D495/04 ; A61P35/00
Abstract:
The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins with compositions of Formula (II-A). The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions of Formula (II-A) for use in these methods are also provided.
Public/Granted literature
- US20210101908A1 SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE Public/Granted day:2021-04-08
Information query
